EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Phenotypic characterization of disease‐initiating stem cells in JAK2 ‐ or CALR ‐mutated myeloproliferative neoplasms

Daniel Ivanov iD, Jelena D Milosevic Feenstra iD, Irina Sadovnik iD, Harald Herrmann, Barbara Peter iD, Michael Willmann iD, Georg Greiner iD, Katharina Slavnitsch, Emir Hadzijusufovic iD, Thomas Rülicke iD, Maik Dahlhoff iD, Gregor Hoermann iD und 13 weitere

American Journal of Hematology · 2023-05 · 98 (5) · 770-783

DOI: 10.1002/ajh.26889 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Hematology, online erschienen am 09.03.2023. Verfasst von Daniel Ivanov und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Myeloproliferative Disorders, Polycythemia Vera. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Myeloproliferative neoplasms (MPN) are characterized by uncontrolled expansion of myeloid cells, disease‐related mutations in certain driver‐genes including JAK2 , CALR , and MPL , and a substantial risk to progress to secondary acute myeloid leukemia (sAML). Although behaving as stem cell neoplasms, little is known about disease‐initiating stem cells in MPN. We established the phenotype of putative CD34 + /CD38 − stem cells and CD34 + /CD38 + progenitor cells in MPN. A total of 111 patients with MPN suffering from polycythemia vera, essential thrombocythemia, or primary myelofibrosis (PMF) were examined. In almost all patients tested, CD34 + /CD38 − stem cells expressed CD33, CD44, CD47, CD52, CD97, CD99, CD105, CD117, CD123, CD133, CD184, CD243, and CD274 (PD‐L1). In patients with PMF, MPN stem cells often expressed CD25 and sometimes also CD26 in an aberrant manner. MPN stem cells did not exhibit substantial amounts of CD90, CD273 (PD‐L2), CD279 (PD‐1), CD366 (TIM‐3), CD371 (CLL‐1), or IL‐1RAP. The phenotype of CD34 + /CD38 − stem cells did not change profoundly during progression to sAML. The disease‐initiating capacity of putative MPN stem cells was confirmed in NSGS mice. Whereas CD34 + /CD38 − MPN cells engrafted in NSGS mice, no substantial engraftment was produced by CD34 + /CD38 + or CD34 − cells. The JAK2‐targeting drug fedratinib and the BRD4 degrader dBET6 induced apoptosis and suppressed proliferation in MPN stem cells. Together, MPN stem cells display a unique phenotype, including cytokine receptors, immune checkpoint molecules, and other clinically relevant target antigens. Phenotypic characterization of neoplastic stem cells in MPN and sAML should facilitate their enrichment and the development of stem cell‐eradicating (curative) therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteMyeloproliferative DisordersPolycythemia VeraAnimalsMiceCalreticulinJanus Kinase 2MutationNeoplastic Stem CellsNuclear ProteinsPhenotypeTranscription FactorsHumansAcetamidesIndolesPiperidines

Substanzen

CalreticulinJanus Kinase 2Nuclear ProteinsTranscription FactorsdBET6AcetamidesIndolesPiperidines

Autor:innen und Institutionen

  • Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria.
  • Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.
  • Department of Radiation Oncology, Medical University of Vienna, Vienna, Austria.
  • Department for Companion Animals, Clinical Unit for Internal Medicine, University of Veterinary Medicine Vienna, Vienna, Austria.
  • Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.
  • Ihr Labor, Medical Diagnostic Laboratories, Vienna, Austria.

ORCID-Profile: Daniel Ivanov, Jelena D Milosevic Feenstra, Irina Sadovnik, Barbara Peter, Michael Willmann, Georg Greiner, Emir Hadzijusufovic, Thomas Rülicke, Maik Dahlhoff, Gregor Hoermann, Gregor Eisenwort, Michael Fillitz, Maria-Theresa Krauth, Wolfgang R Sperr, Elisabeth Koller, Heinz Gisslinger, Robert Kralovics, Peter Valent

Zitieren

APA

Ivanov, D., Milosevic Feenstra, J. D., Sadovnik, I., Herrmann, H., Peter, B., Willmann, M., Greiner, G., Slavnitsch, K., Hadzijusufovic, E., Rülicke, T., Dahlhoff, M., Hoermann, G., Machherndl-Spandl, S., Eisenwort, G., Fillitz, M., Sliwa, T., Krauth, M. T., Bettelheim, P., Sperr, W. R., …, & Valent, P. (2023). Phenotypic characterization of disease‐initiating stem cells in JAK2 ‐ or CALR ‐mutated myeloproliferative neoplasms. American Journal of Hematology, 98(5), 770-783. https://doi.org/10.1002/ajh.26889

Vancouver

Ivanov D, Milosevic Feenstra JD, Sadovnik I, Herrmann H, Peter B, Willmann M, et al. Phenotypic characterization of disease‐initiating stem cells in JAK2 ‐ or CALR ‐mutated myeloproliferative neoplasms. American Journal of Hematology. 2023;98(5):770-783. doi:10.1002/ajh.26889

BibTeX
@article{Ivanov2023,
  author = {Ivanov, Daniel and Milosevic Feenstra, Jelena D and Sadovnik, Irina and Herrmann, Harald and Peter, Barbara and Willmann, Michael and Greiner, Georg and Slavnitsch, Katharina and Hadzijusufovic, Emir and Rülicke, Thomas and Dahlhoff, Maik and Hoermann, Gregor and Machherndl-Spandl, Sigrid and Eisenwort, Gregor and Fillitz, Michael and Sliwa, Thamer and Krauth, Maria-Theresa and Bettelheim, Peter and Sperr, Wolfgang R and Koller, Elisabeth and Pfeilstöcker, Michael and Gisslinger, Heinz and Keil, Felix and Kralovics, Robert and Valent, Peter},
  title = {Phenotypic characterization of disease‐initiating stem cells in JAK2 ‐ or CALR ‐mutated myeloproliferative neoplasms},
  journal = {American Journal of Hematology},
  year = {2023},
  volume = {98},
  number = {5},
  pages = {770--783},
  doi = {10.1002/ajh.26889}
}
Kostenlos starten →